Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 22Breast Neoplasms 19Lymphoma 14Sarcoma 13Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 8Lymphoma, B-Cell 8Hodgkin Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Primary Effusion 3Chondrosarcoma 3Triple Negative Breast Neoplasms 2Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Plasmablastic Lymphoma 2Osteosarcoma 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Liver Neoplasms 2

Interventions

selinexor 1seclidemstat 1pazopanib 1Topotecan 1Proton Therapy 1Ifosfamide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Histiocytoma, Angiomatoid Fibrous × Doxorubicin × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡